Emisphere Tech (EMIS) 0.6600 $EMIS Emisphere Te
Post# of 273331
Posted On: 04/12/2015 8:49:53 AM
Emisphere Tech (EMIS) 0.6600 $EMIS
Emisphere Technologies' (EMIS) CEO Alan Rubino on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 31, 10:15AM CDT
Emisphere Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 6:50AM CDT
Recent Launch of Eligen B12(TM) Marks Company's Expansion into Commercializing Practical Innovation
Emisphere Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call
GlobeNewswire - Wed Mar 25, 3:20PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call on Tuesday, March 31, 2015, at 8:30 AM ET to discuss the Company's financial and operational results for the quarter and twelve months that ended December 31, 2014.
Key Aspects Of A Potential Novo Nordisk Oral GLP-1 Phase 3 Trial
PLM Investments - at Seeking Alpha - Fri Mar 20, 10:52AM CDT
NVO: 55.94 (+1.34)
Penny Stocks Alerts for Sabine Oil & Gas, HDS International, Integral Technologies, Quicksilver Resources, FLEXPOWER, and Emisphere
PR Newswire - Thu Mar 19, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Sabine Oil & Gas (OTCMKTS:SOGC), HDS International (OTCMKTS:HDSI), Integral Technologies (OTCMKTS:ITKG), Quicksilver Resources (OTCMKTS:KWKA), FLEXPOWER (OTCMKTS:FLXP), and Emisphere Technologies (OTCMKTS:EMIS).
Emisphere Launches Eligen B12(TM), the First Oral Prescription Tablet Proven to Normalize B12 Levels Without the Need for an Injection
PR Newswire - Thu Mar 19, 7:15AM CDT
Emisphere Technologies, Inc. (OTCBB: EMIS) today announced the U.S. commercial availability of Eligen B12(TM), the first and only once-daily oral prescription medical food tablet shown to normalize B12 levels without the need for an injection. Eligen B12 is indicated for the dietary management of patients who have a medically-diagnosed vitamin B12 deficiency, associated with a disease or condition that cannot be managed by a modification of the normal diet alone.
Novo Nordisk Is In The NASH Space, Too
PLM Investments - at Seeking Alpha - Wed Mar 18, 6:52PM CDT
NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), ICPT: 279.25 (+7.48)
Novo-Nordisk's Oral GLP-1 Diabetes Treatment: An Update
PLM Investments - at Seeking Alpha - Thu Feb 19, 10:25AM CST
NVO: 55.94 (+1.34)
Emis Group's (EMIS) CEO Alan Rubino on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:25PM CST
Emisphere Tech Q3 results
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:13AM CST
Emisphere Technologies EPS of -$0.24
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:36AM CST
Emisphere Technologies Announces Financial Results for the Third Quarter 2014
GlobeNewswire - Fri Nov 14, 7:00AM CST
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced its financial results for the quarter ended September 30, 2014. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.
Emisphere reports November 14
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:34AM CST
Emisphere Technologies Announces Third Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Nov 12, 7:00AM CST
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended September 30, 2014 on Friday, November 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening.
Emisphere enters into USD20m debt financing to introduce oral Eligen B12 in the US market
M2 - Thu Aug 21, 7:31AM CDT
Pharmaceutical company Emisphere Technologies (OTC BB:EMIS) reported on Wednesday the execution of new loan facility agreement to finance the upcoming launch of its first commercial prescription product oral Eligen B12 in the US for B12 deficient individuals.
Emisphere Announces $20 Million Debt Financing to Launch Oral Eligen(R) B12
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced that it has reached agreement with MHR Fund Management LLC, and certain of its affiliated funds ("MHR" , to finance the upcoming launch of the Company's first commercial prescription product, oral Eligen B12 in the United States through a new loan facility, and to amend the terms of the Company's existing obligations under various promissory notes previously issued to MHR to extend the maturity dates of such promissory notes.
Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
NVO: 55.94 (+1.34), ORMP: 6.23 (+0.06), TTHI: 6.99 (+0.08), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51)
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended June 30, 2014
GlobeNewswire - Thu Aug 14, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced its financial results for the quarter ended June 30, 2014. The Company will host a conference call on Thursday, August 14, at 8:30 AM ET to discuss these results.
Emisphere Technologies, Inc. Announces Second Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Aug 13, 12:11PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended June 30, 2014 on Thursday, August 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening.
Emisphere Technologies' (EMIS) CEO Alan Rubino on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 31, 10:15AM CDT
Emisphere Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 6:50AM CDT
Recent Launch of Eligen B12(TM) Marks Company's Expansion into Commercializing Practical Innovation
Emisphere Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call
GlobeNewswire - Wed Mar 25, 3:20PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call on Tuesday, March 31, 2015, at 8:30 AM ET to discuss the Company's financial and operational results for the quarter and twelve months that ended December 31, 2014.
Key Aspects Of A Potential Novo Nordisk Oral GLP-1 Phase 3 Trial
PLM Investments - at Seeking Alpha - Fri Mar 20, 10:52AM CDT
NVO: 55.94 (+1.34)
Penny Stocks Alerts for Sabine Oil & Gas, HDS International, Integral Technologies, Quicksilver Resources, FLEXPOWER, and Emisphere
PR Newswire - Thu Mar 19, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Sabine Oil & Gas (OTCMKTS:SOGC), HDS International (OTCMKTS:HDSI), Integral Technologies (OTCMKTS:ITKG), Quicksilver Resources (OTCMKTS:KWKA), FLEXPOWER (OTCMKTS:FLXP), and Emisphere Technologies (OTCMKTS:EMIS).
Emisphere Launches Eligen B12(TM), the First Oral Prescription Tablet Proven to Normalize B12 Levels Without the Need for an Injection
PR Newswire - Thu Mar 19, 7:15AM CDT
Emisphere Technologies, Inc. (OTCBB: EMIS) today announced the U.S. commercial availability of Eligen B12(TM), the first and only once-daily oral prescription medical food tablet shown to normalize B12 levels without the need for an injection. Eligen B12 is indicated for the dietary management of patients who have a medically-diagnosed vitamin B12 deficiency, associated with a disease or condition that cannot be managed by a modification of the normal diet alone.
Novo Nordisk Is In The NASH Space, Too
PLM Investments - at Seeking Alpha - Wed Mar 18, 6:52PM CDT
NVO: 55.94 (+1.34), GILD: 101.77 (+0.61), ICPT: 279.25 (+7.48)
Novo-Nordisk's Oral GLP-1 Diabetes Treatment: An Update
PLM Investments - at Seeking Alpha - Thu Feb 19, 10:25AM CST
NVO: 55.94 (+1.34)
Emis Group's (EMIS) CEO Alan Rubino on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:25PM CST
Emisphere Tech Q3 results
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:13AM CST
Emisphere Technologies EPS of -$0.24
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:36AM CST
Emisphere Technologies Announces Financial Results for the Third Quarter 2014
GlobeNewswire - Fri Nov 14, 7:00AM CST
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced its financial results for the quarter ended September 30, 2014. The Company will host a conference call this morning at 8:30 AM ET to discuss these results. Emisphere reports November 14
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:34AM CST
Emisphere Technologies Announces Third Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Nov 12, 7:00AM CST
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company"
announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended September 30, 2014 on Friday, November 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening. Emisphere enters into USD20m debt financing to introduce oral Eligen B12 in the US market
M2 - Thu Aug 21, 7:31AM CDT
Pharmaceutical company Emisphere Technologies (OTC BB:EMIS) reported on Wednesday the execution of new loan facility agreement to finance the upcoming launch of its first commercial prescription product oral Eligen B12 in the US for B12 deficient individuals.
Emisphere Announces $20 Million Debt Financing to Launch Oral Eligen(R) B12
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced that it has reached agreement with MHR Fund Management LLC, and certain of its affiliated funds ("MHR" , to finance the upcoming launch of the Company's first commercial prescription product, oral Eligen B12 in the United States through a new loan facility, and to amend the terms of the Company's existing obligations under various promissory notes previously issued to MHR to extend the maturity dates of such promissory notes. Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
NVO: 55.94 (+1.34), ORMP: 6.23 (+0.06), TTHI: 6.99 (+0.08), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51)
Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended June 30, 2014
GlobeNewswire - Thu Aug 14, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company"
today announced its financial results for the quarter ended June 30, 2014. The Company will host a conference call on Thursday, August 14, at 8:30 AM ET to discuss these results. Emisphere Technologies, Inc. Announces Second Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Aug 13, 12:11PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company"
announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended June 30, 2014 on Thursday, August 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening. 
(0)
(0)